Free tool
FAERS Monitor: Loargys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761211 or its brand name (Loargys, Pegzilarginase-Nbln). Reports on generic versions are filed under their own applications.
Reports
31
Serious
23
74% of reports
Hospitalization
18
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyperammonaemia12
- ammonia increased8
- decreased appetite5
- vomiting5
- pyrexia4
- somnolence4
- hyperammonaemic crisis3
- amino acid level increased2
- aphthous ulcer2
- arginine level decreased2
- asthenia2
- coma2
- condition aggravated2
- drug monitoring procedure incorrectly performed2
- feeding disorder2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| arginine level decreased | 2 | 1358330.8 | 126401.6 | 509,373 |
| hyperammonaemic crisisSignal | 3 | 19591.3 | 6570.5 | 39,666 |
| drug monitoring procedure incorrectly performed | 2 | 2055.0 | 536.7 | 2,302 |
| amino acid level increased | 2 | 1833.1 | 478.8 | 2,054 |
| hyperammonaemiaSignal | 12 | 1632.0 | 1047.0 | 17,924 |
| ammonia increasedSignal | 8 | 1065.6 | 586.2 | 7,467 |
| aphthous ulcer | 2 | 175.0 | 45.8 | 194 |
| feeding disorder | 2 | 66.9 | 17.5 | 72 |
| coma | 2 | 28.5 | 7.5 | 29 |
| decreased appetiteSignal | 5 | 14.6 | 6.5 | 51 |
| somnolenceSignal | 4 | 13.5 | 5.4 | 35 |
| pyrexiaSignal | 4 | 7.8 | 3.1 | 18 |
| vomitingSignal | 5 | 7.2 | 3.2 | 21 |
| condition aggravated | 2 | 4.5 | 1.2 | 3 |
| asthenia | 2 | 3.6 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.